DELCATH SYSTEMS INC
DCTHNASDAQTrading Snapshot
- Day Range
- $392.55 – $396.97
- 52-Week Range
- $8.12 – $17.42
- Volume
- $3.61B
- Avg Volume
- $2.89B
- Shares Outstanding
- 34.5M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $85M
- Last Q Revenue
- $29M
- P/E Ratio
- 1437.3
- P/S Ratio
- 5.7x
- EPS (TTM)
- $0.01
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +40.1%
Why Investors Own DCTH
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DELCATH SYSTEMS INC
DCTH
StockOtter · stockotter.spaceAbout DELCATH SYSTEMS INC
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
DELCATH SYSTEMS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift DCTH price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
DELCATH SYSTEMS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.